Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNISHAPE-OSA-1
ChiCTR2600135162Phase 3Not yet recruiting
- Sponsor
- Peking University People's Hospital
- Start
- Sep 2026
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of UBT251 in obstructive sleep apnea hypopnea syndrome (OSAHS) and obesity (4 arms), sponsored by Peking University People's Hospital. Primary endpoint: Change in Apnea-Hypopnea Index (AHI) from baseline at week 52. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
UBT251
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)obesity
Beyond the preview
Go deeper on ChiCTR2600135162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600135162.